Runben Biotechnology Dividends and Buybacks
Dividend criteria checks 3/6
Runben Biotechnology is a dividend paying company with a current yield of 0.76% that is well covered by earnings.
Key information
0.8%
Dividend yield
-10.3%
Buyback Yield
| Total Shareholder Yield | -9.6% |
| Future Dividend Yield | 1.1% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.180 |
| Payout ratio | 46% |
Recent dividend and buyback updates
No updates
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Too early to tell whether 603193's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 603193's dividend payments are increasing as they only just started paying a dividend.
Dividend Yield vs Market
| Runben Biotechnology Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (603193) | 0.8% |
| Market Bottom 25% (CN) | 0.5% |
| Market Top 25% (CN) | 2.1% |
| Industry Average (Personal Products) | 2.4% |
| Analyst forecast (603193) (up to 3 years) | 1.1% |
Notable Dividend: 603193's dividend (0.76%) is higher than the bottom 25% of dividend payers in the CN market (0.54%).
High Dividend: 603193's dividend (0.76%) is low compared to the top 25% of dividend payers in the CN market (2.09%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (46.1%), 603193's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (37.5%), 603193's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 19:10 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Runben Biotechnology Co., Ltd. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiyue Zhang | Chasing Securities |
| Junhao Fan | China International Capital Corporation Limited |
| Zhuonan Xu | China International Capital Corporation Limited |